The Take Control of Your Blood Pressure trial randomized 636 com munity-dwelling individuals with hypertension to evaluate the impact of a telephonic behavioral self-management intervention, home blood pressure monitoring, and both interventions combined compared to usual care on reducing systolic blood pressure (SBP) over 24 months. At 24 months, the combined intervention demonstrated a sig nificant 3.9 mmHg (95%CI: 0.9,6.9) reduction in SBP relative to usual care. Patients randomized to home BP monitoring or the behavioral intervention had less improve ment (0.6 mmHg and 0.6 mmHg, respectively). A prospective economic evaluation was performed. METHODS: Measures of medical resource use costs were derived from electronic data representing medical care delivered within the Duke University Health System. Intervention-related costs, including patient time, were estimated using patient-level data collected during the trial, administrative records, and published unit costs. Sensitivity analyses were conducted to evaluate the impact of changing assump tions about overhead costs and time between completed phone encounters when esti mating costs associated with the behavioral intervention. RESULTS: On average, over 24 months, patients incurred $6,965 (SD 22,054) in inpatient costs and $8,676 (SD 9,368) in outpatient costs, with no significant differences across intervention groups. When applying base-case assumptions, 24-month intervention costs were estimated to be $90 (SD 2) for home blood pressure monitoring, $345 (SD 64) for the behav ioral intervention ($31 per phone encounter) and $416 (SD 93) for the combined intervention. In sensitivity analyses, the cost for each phone encounter ranged from approximately $10 to $45. Patient time costs were estimated at $585 (SD 487) for home monitoring, $55 (SD 16) for the behavioral intervention and $741 (SD 529) for the combined intervention. CONCLUSIONS: Home blood pressure monitoring and/or the behavioral intervention had little impact on medical resource use or costs over 2 years. Our analysis demonstrated that these interventions are cost-additive to the health care system and that patients' time costs are considerable.
PCV59 ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II TRIAL
To assessed the economic attractiveness of the Endeavor drug-eluting stent (DES) vs. the Driver bare metal stent (BMS) using 4-year follow-up information from the ENDEAVOR II clinical trial. METHODS: We used clinical, index procedure and follow-up events data from subjects randomized to receive Endeavor (n 598) vs. Driver (n 599), and applied Medicare cost and quality of life adjustments from secondary sources. We compared differences in clinical endpoints, medical costs, and quality adjusted survival through 4 years follow-up (1440 days). RESULTS: Patients in both treatment groups had similar baseline characteristics. A 1 year follow-up period was used and costs incurred after patients' initial hospital discharge were examined. In addition to ordinary least squares (OLS),, quantile-regression models (QRM) were used to identify drivers of post hospital costs. QRM make no assumption about the distribution of the error term and provide quantile-specific covariate effects, which is useful in applications with highly skewed data. RESULTS: OLS results indicated co-morbidity scores, prior health care costs and initial hospital diagnosis were main drivers of post-hospital discharge costs (p 0.01). Also, revascularization procedures during the initial hospitalization were not significantly associated with post-hospital costs. QRM con firmed the other findings but showed, at the lower end of the post-hospital costs dis tribution, having revascularization procedures during the initial hospitalization was significantly associated with higher post-hospital costs. This effect was not significant in the upper quantiles. CONCLUSIONS: In this study, initial hospital diagnosis, higher co-morbidity scores and prior health care costs were associated with higher post hospital costs. Also, QRM showed revascularization procedures were drivers of cost for patients with lower post-hospital expenditures. This is an intuitive finding con sidering patients who have revascularization procedures may have more follow-up care compared to those without revascularization. However, these patients may have fewer secondary events requiring hospitalization, thus keeping them in the lower cost quantiles.
PCV62 IDENTIFYING DRIVERS OF POST-HOSPITAL DISCHARGE FOR PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) USING QUANTILE REGRESSIONS

